• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » FDA panel: Novocure’s brain tumor device improves quality of life but not survival rate

FDA panel: Novocure’s brain tumor device improves quality of life but not survival rate

March 16, 2011 By MassDevice staff

glioblastoma

A revolutionary treatment for a deadly form of brain cancer failed to show a significant increase in the overall survivability rate when measured against chemotherapy, according to an FDA reviewers document posted on the agency’s web site.

In reviewer materials released ahead of a March 17 meeting of the FDA’s neurological devices panel, Food & Drug Administration officials questioned claims made by NovoCure, a privately-held Israeli company, which is seeking pre-market approval for its NovoTTF-100A device.

The document said clinical trials of the device, described by the company as a “non-invasive device, consisting of four sets of insulated electrodes attached to an electronic box,” failed to show a significant increase in overall survivability rate when compared to the standard treatment of aggressive chemotherapy.

The one-year survival rate for patients using the NovoTTF devices versus chemotherapy was essentially the same, at 21.9 percent versus 22.1 percent using the FDA’s strict statistical measurements. Adjusted for the protocol set up in NovoCure’s clinical study, survival rate at one year was slightly higher at 27.8 percent, compared to 21.6 percent.

The biggest difference in the treatments came from quality-of-life scores in post-study patient surveys, which showed a significantly higher quality of life using the NovoCure device when compared to chemotherapy. In particular, patents reported significantly fewer instances of sever gastrointestinal distress including, nausea, vomiting, diarrhea, constipation and pain.

The NovoCure device did have a higher incident rate of convulsions, headaches and mental status changes, which the panel said it would ask company officials about during the March 17 review. However, the document did preface that convulsions are “expected in 20-50% of GBM subjects at various stages of their disease” and that the incidence of convulsions in this trial was low compared to other trials.

The FDA hasn’t made its final decision on the company’s PMA, but did ask questions about a post-market study of the device, stipulating that this shouldn’t be “interpreted to mean that FDA has made a decision on the approvability of this PMA device.”

The agency is considering the device as a treatment for glioblastoma “after surgical and radiation options have been exhausted,” according to a note in the Federal Register. Glioblastoma is the most common form of brain tumor and has a low survival rate.

Patients using the device, which resembles a cap of bandages with electrodes attached, are given continuous low-intensity, alternating electric fields directly to the tumor site. Patients undergoing the treatment are expected to continue wearing the device for more than 18 hours a day.
NovoCure was founded in 2000 by Yoram Palti, a former researcher at the Technion-Israel Institute of Technology. The company has been conducting a Phase III clinical trial of the device since June 2009. NovoCure counts New York-based venture capital firm WFD Ventures as a primary investor.

Filed Under: Neuromodulation/Neurostimulation, News Well, Oncology Tagged With: NovoCure

In case you missed it

  • 16 surgical robotics companies you need to know
  • Report: Elon Musk looks to invest in brain-computer interface competitor Synchron
  • AI-powered imaging startup AIRS Medical raises $20M Series B
  • Analysts ask: Can Medtronic leaders execute?
  • Medtronic announces cash dividend for Q2 2023
  • EchoNous partners with Samsung on AI-guided ultrasound
  • RefleXion expands footprint through multi-system contract with Select Healthcare
  • Report: 3M faces losses of $100B in earplug lawsuits
  • Caregility, Eko partner to bring smart stethoscope to telehealth platform
  • Henry Schein makes $400M increase to share repurchase plan
  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • CathVision closes $7.2M financing round for electrophysiology recording tech
  • Verily’s Onduo, Sword Health collaborate on virtual care
  • FDA clears expanded labeling for Preceptis Medical’s ear tube system
  • KeyCare raises $24M for virtual care platform
  • FDA says 44 more deaths have been reported in Philips ventilator recall
  • Paragonix reaches milestone of 2,000 organs preserved, transported for transplantation

RSS From Medical Design & Outsourcing

  • MIT engineers fabricate chip-free, wireless e-skin
    MIT engineers have developed a new wireless, wearable sensor without semiconductors or batteries in what they say is a first step toward chip-free wireless sensors. This electronic skin — or e-skin — is a flexible, semiconducting film that MIT describes as a sort of electronic Scotch tape. The device has an ultrathin gallium nitride film… […]
  • Owens & Minor and Allina Health partner on supply chain resiliency
    Owens & Minor (NYSE: OMI) and Minneapolis-based Allina Health are partnering on what they call a “unique integrated service model for supply chain resiliency.” An Owens & Minor distribution center that has been in operation for more than 25 years in Moundsview, Minnesota will serve as the integrated service center powering the model, the companies… […]
  • Chronic pain researchers say sound and electrical stimulation has treatment potential
    University of Minnesota researchers are using sound and electrical stimulation to treat chronic pain and other sensory disorders without pharmaceutical drugs. The combination of sound and stimulation activates the brain’s somatosensory cortex, according to a study on guinea pigs published in the Journal of Neural Engineering. Also known as the tactile cortex, the somatosensory cortex is… […]
  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 19, 2022
DTW - What’s the state of the Medtech job market? We go to the pros to hear things you need to know
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy